IP Library Granted Patent US 6,890,763
Granted Patent B2
US 6,890,763 · App. 09/845,729 · Granted May 10, 2005

Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,890,763
App. No.
09/845,729
Granted
May 10, 2005
Kind
B2
Abstract

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer.

Claims (10)

1. An isolated peptide consisting of SEQ ID NO: 1.

2. A method for determining the presence of the peptide of claim 1 comprising:

(a) providing a mass spectrum profile of SEQ ID NO: 1;

(b) obtaining a sample from a patient;

(c) conducting mass spectrometric analysis on said sample in a manner effective to maximize elucidation of discernible peptide fragments contained therein, and comparing the mass spectrum profiles of SEQ ID NO: 1 to the mass spectrum profiles of peptides elucidated from said sample; and

(d) confirming the presence of SEQ ID NO: 1 in said sample by detecting the presence of a peak profile at about 1350 Da in said mass spectrum profile.

3. The method of claim 2 , wherein the sample is an unfractionated body fluid or a tissue sample.

4. The method of claim 2 , wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

5. The method of claim 2 , wherein said mass spectrometric analysis is Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS).

6. The method of claim 2 , wherein said patient is a human.